ЗНАЧЕНИЕ ЭПИДЕМИОЛОГИЧЕСКИХ ИССЛЕДОВАНИЙ В ПУЛЬМОНОЛОГИИ
https://doi.org/10.18093/0869-0189-2014-0-1-
Аннотация
О роли эпидемиологических исследований в пульмонологии.
Об авторах
В. В. Архипов
ГБОУ ВПО "Первый Московский государственный медицинский университет им. И.М.Сеченова" Минздрава России: 109240, Москва, ул. Яузская 11, ГКБ № 23
Россия
д. м. н., профессор кафедры клинической фармакологии и пропедевтики внутренних болезней ГБОУ
ВПО "Первый Московский государственный медицинский университет им. И.М.Сеченова" Минздрава России, ГКБ № 23; тел.: (495) 915-59-89
Россия
д. м. н., профессор кафедры клинической фармакологии и пропедевтики внутренних болезней ГБОУ
ВПО "Первый Московский государственный медицинский университет им. И.М.Сеченова" Минздрава России, ГКБ № 23; тел.: (495) 915-59-89
Д. Е. Архипова
ГБОУ ВПО "Первый Московский государственный медицинский университет им. И.М.Сеченова" Минздрава России: 109240, Москва, ул. Яузская 11, ГКБ № 23
Россия
к. м. н., ассистент кафедры клинической фармакологии и пропедевтики внутренних болезней ГБОУ ВПО
"Первый Московский государственный медицинский университет им. И.М.Сеченова" Минздрава России, ГКБ № 23; тел.: (495) 915-59-89
Россия
к. м. н., ассистент кафедры клинической фармакологии и пропедевтики внутренних болезней ГБОУ ВПО
"Первый Московский государственный медицинский университет им. И.М.Сеченова" Минздрава России, ГКБ № 23; тел.: (495) 915-59-89
Список литературы
1. Travers J., Marsh S., Caldwell B. et al. External validity of randomized controlled trials in COPD. Respir Med. 2007; 101 (6): 1313–1320.
2. Tashkin D.P., Celli B., Senn S. et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359 (15): 1543–1554.
3. Tonnel A.B., Perez T., Grosbois J.M. et al. Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2008; 3(2): 301–310.
4. Fležar M., Jahnz-Rózyk K., Enache G. et al. SOSPES: SPIRIVA® observational study measuring SGRQ score in routine medical practice in Central and Eastern Europe. Int. J. COPD 2013; 8: 483–492.
5. Lisspers K., Larsson K., Ställberg B. et al. COPD in primary care in Sweden – an 11 years epidemiological register study. ERS 2012; Abs. 4339.
6. Szafranski W., Cukier A., Ramirez A. et al. Efficacy and safety of budesonide / formoterol in the management of chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 21: 74–81.
7. Soriano J.B., Kiri V.A., Pride N.B., Vestbo J. Inhaled corticosteroids with / without long-acting beta-agonists reduce the risk of rehospitalization and death in COPD patients. Am. J. Respir. Med. 2003; 2 (1): 67–74.
8. Calverley P., Pauwels R., Vestbo J. et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361: 449–456.
9. Calverley P.M., Anderson J.A., Celli B. et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007; 356 (8):775–789.
10. Vestbo J., Anderson J. A., Calverley P. M. et al. Bias due to withdrawal in long-term randomized trials in COPD: evidence from the TORCH study. Clin. Respir. J. 2011; 5: 44–49.
11. Suissa S. Medications to modify lung function decline in chronic obstructive pulmonary disease: some hopeful signs. Am. J. Respir. Crit. Care Med. 2008; 178 (4): 322–323.
12. Lachin J.M. Statistical considerations in the intent-to-treat principle. Control. Clin. Trials. 2000; 21 (3): 167–189.
13. Celli B.R., Thomas N.E., Anderson J.A. et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am. J. Respir. Crit. Care Med. 2008; 178 (4): 332–338.
14. Miles M.C., Donohue J.F., Ohar J.A. Combination therapy for COPD: emerging evidence from recent clinical trials. Clin. Invest. 2011; 1 (6): 879–890.
15. Suissa S., Ernst P., Vandemheen K.L., Aaron S.D. Methodological issues in therapeutic trials of COPD. Eur. Respir. J. 2008; 31: 927–933.
16. Wedzicha J.A., Calverley P.M., Seemungal T.A. et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol / fluticasone propionate or tiotropium bromide. Am. J. Respir. Crit. Care Med. 2008; 177 (1): 19–26.
17. Suissa S. Methodologic shortcomings of the INSPIRE randomized trial. Am. J. Respir. Crit. Care Med. 2008; 178 (10): 1090–1091.
18. Tonelli M.R., Curtis J.R., Guntupalli K.K. et al. An official multi-society statement: The role of clinical research results in the practice of critical care medicine. Am. J. Respir. Crit. Care Med. 2012; 185 (10): 1117–1124.
19. MacPherson H. Pragmatic clinical trials. Complement Ther. Med. 2004; 12 (2–3): 136–140.
20. Vogelmeier C., D'Urzo A., Pauwels R. et al. Budesonide / formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur. Respir. J. 2005; 26: 819–828.
21. Suissa S., Ernst P., Boivin J.F. et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am. J. Respir. Crit. Care Med. 1994; 149 (3, Pt 1): 604–610.
22. Suissa S., Ernst P., Benayoun S. et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. N. Engl. J. Med. 2000; 343 (5): 332–336.
23. Sears M.R., Taylor D.R. The beta 2-agonist controversy. Observations, explanations and relationship to asthma epidemiology. Drug Saf. 1994; 11 (4): 259–283.
24. Suissa S., Dell'Aniello S., Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax 2012; 67 (11): 957–963.
25. http://www.cebm.net/index.aspx?o=8117 26. http://www.cebm.net/mod_product/design/files/CEBMLevels-of-Evidence-2.1.pdf
26. Larsson K., Janson C., Lisspers K. et al. Combination of budesonide / formoterol more effective than fluticasone / salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study. J. Intern. Med. 2013; 273 (6): 584–594.
27. Janson C., Larsson K., Lisspers K.H. et al. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting b2-agonist: observational matched cohort study (PATHOS). Br. Med. J. 2013; 346: f3306. Doi: 10.1136/bmj.f3306.
28. Joffe M.M., Rosenbaum P.R. Invited commentary: propensity scores. Am. J. Epidemiol. 1999; 150: 327–233.
29. Perkins S.M., Tu W., Underhill M.G. et al. The use of propensity scores in pharmacoepidemiologic research. Pharmacoepidemiol. Drug Saf. 2000; 9: 93–101.
30. Battram C., Charlton S.J., Cuenoud B. et al. In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action. J. Pharmacol. Exp. Ther. 2006; 317 (2): 762–770.
31. Partridge M.R., Schuermann W., Beckman O. et al. Effect on lung function and morning activities of budesonide / formoterol versus salmeterol/fluticasone in patients with COPD. Ther. Adv. Respir. Dis. 2009; 3 (4): 1–11.
32. Lindberg A., Szalai Z., Pullerits T., Radeczky E. Fast onset of effect of budesonide / formoterol versus salmeterol / fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction. Respirology 2007; 12 (5): 732–739.
33. Borgström L., Asking L., Thorsson L. Idealhalers or realhalers? A comparison of Diskus and Turbuhaler. Int. J. Clin. Pract. 2005; 59 (12): 1488–1495.
34. Bisgaard H., ed. Drug delivery to the lung. New York: Marcel Dekker, Inc. 2001. 437–438.
35. Vogelmeier C., Hederer B., Glaab T. et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N. Engl. J. Med. 2011; 364 (12): 1093–1103.
36. Ek A., Larsson K., Siljerud S., Palmberg L. Fluticasone and budesonide inhibit cytokine release in human lung epithelial cells and alveolar macrophages. Allergy 1999; 54 (7): 691–699.
37. Pedersen S., O'Byme I. A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy 1997: 52 (Suppl. 39): 1–34.
38. Miller-Larsson A., Jansson P., Runström A., Brattsand R. Prolonged airway activity and improved selectivity of budesonide possibly due to esterification. Am. J. Respir. Crit. Care Med. 2000; 162 (4, Pt 1): 1455–1461.
39. Zalacain R., Sobradillo V., Amilibia J. et al. Predisposing factors to bacterial colonization in chronic obstructive pulmonary disease. Eur. Respir. J. 1999; 13 (2): 343–348.
40. Wedzicha J.A., Brill S.E., Allinson J.P., Donaldson G.C. Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease. BMC Med. 2013; 11: 181.
41. Blais L., Forget A., Ramachandran S. Relative effectiveness of budesonide / formoterol and fluticasone propionate / salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence. Clin. Ther. 2010; 32 (7): 1320–1328.
42. Ferguson G.T., Anzueto A., Fei R. et al. Effect of fluticasone propionate / salmeterol (250 / 50 microg) or salmeterol (50 microg) on COPD exacerbations. Respir. Med. 2008; 102 (8): 1099–1108.
43. Calverley P.M.A., Dransfield M.T., Bourbeau J. et al. Safety of fluticasone furoate (FF), an inhaled corticosteroid in combination with vilanterol (VI), a long-acting beta agonist in management of COPD exacerbations. ERS congress abstract 2012. Abs. 2113; http://www.ers-education.org/ersMade/abstract_print_12/main_frameset.htm
44. Halpin D.M., Gray J., Edwards S.J. et al. Budesonide / formoterol vs salmeterol / fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials. Int. J. Clin. Pract. 2011; 65 (7): 764–774.
45. Sin D.D., Tashkin D., Zhang X. et al. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet 2009; 374 (9691): 712–719.
46. Sin D., Tashkin D., Radner F. et al. Risk of pneumonia related to budesonide use in COPD: An updated pooled analysis. ERS congress abstract 2012. Abs. 2117; http://www.ers-education.org/ersMade/abstract_print_12/main_frameset.htm
47. Suissa S., Patenaude V., Lapi F., Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax 2013; 68: 1029–1036.
48. Aaron S.D., Vandemheen K.L., Fergusson D. et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-
49. salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann. Intern. Med. 2007; 146 (8): 545–555.
50. FitzGerald J.M., Boulet L.P., Follows R.M. The CONCEPT trial: A 1-year, multicenter, randomized, double-blind, double-dummy comparison of a stable dosing regimen of salmeterol / fluticasone propionate with an adjustable maintenance dosing regimen of formoterol / budesonide in adults with persistent asthma. Clin. Ther. 2005; 27 (4): 393–406.
51. Guyatt G., Cairns J., Churchill D. et al. Evidence-based medicine. A new approach to teaching the practice of medicine. J.A.M.A. 1992; 268 (17): 2420–2425.
52. Sackett D.L., Rosenberg W.M., Gray J.A. et al. Evidence based medicine: what it is and what it isn't. Br. Med. J. 1996; 312 (7023): 71–72.
53. van der Valk P., Monninkhof E., van der Palen J. et al. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am. J. Respir. Crit. Care Med. 2002; 166 (10):1358–1363.
Рецензия
Для цитирования:
Архипов В.В., Архипова Д.Е. ЗНАЧЕНИЕ ЭПИДЕМИОЛОГИЧЕСКИХ ИССЛЕДОВАНИЙ В ПУЛЬМОНОЛОГИИ. Пульмонология. 2014;(1). https://doi.org/10.18093/0869-0189-2014-0-1-
For citation:
Arkhipov V.V., Arkhipova D.E. A ROLE OF EPIDEMIOLOGICAL STUDIES IN PULMONOLOGY. PULMONOLOGIYA. 2014;(1). (In Russ.) https://doi.org/10.18093/0869-0189-2014-0-1-
Просмотров: 974
Послать статью по эл. почте 